title: Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?
abstract: We evaluated treatment with linezolid, dosed at 800 mg once daily for 1 to 4 months as guided by sputum culture status and tolerance and then at 1,200 mg thrice weekly until ≥ 1 year after culture conversion, in addition to individually optimized regimens among 10 consecutive patients with extensively drug-resistant tuberculosis or fluoroquinolone-resistant multidrug-resistant tuberculosis. All achieved stable cure, with anemia corrected and neuropathy stabilized, ameliorated, or avoided after switching to intermittent dosing. Serum linezolid profiles appeared better optimized.
authors: Tuberculosis and Chest Service, Department of Health, Hong Kong SAR, China.
authors: Kwok-Chiu
authors: KC
authors: Chang
authors: Wing-Wai
authors: WW
authors: Yew
authors: Siu-Wai
authors: SW
authors: Cheung
authors: Chi-Chiu
authors: CC
authors: Leung
authors: Cheuk-Ming
authors: CM
authors: Tam
authors: Chi-Hung
authors: CH
authors: Chau
authors: Peter Kin-Ho
authors: PK
authors: Wen
authors: Raphael Chiu-Yeung
authors: RC
authors: Chan
mesh_terms: D000081:Acetamides / Q000008:administration & dosage* / Q000627:therapeutic use; D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D000069349:Linezolid; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D023303:Oxazolidinones / Q000008:administration & dosage* / Q000627:therapeutic use; D013183:Sputum / Q000382:microbiology; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D000081:Acetamides; D000995:Antitubercular Agents; D023303:Oxazolidinones; D000069349:Linezolid
references: Antimicrob Agents Chemother. 2009 Apr;53(4):1314-9
references: 19075058
references: Antimicrob Agents Chemother. 2002 Aug;46(8):2723-6
references: 12121967
references: Eur J Clin Microbiol Infect Dis. 2004 Apr;23(4):243-55
references: 15024625
references: J Antimicrob Chemother. 2009 Aug;64(2):388-91
references: 19468028
references: J Antimicrob Chemother. 2001 Nov;48(5):605-8
references: 11679548
references: J Antimicrob Chemother. 2002 Jul;50(1):73-7
references: 12096009
references: N Engl J Med. 2012 Oct 18;367(16):1508-18
references: 23075177
references: Antimicrob Agents Chemother. 2002 May;46(5):1475-80
references: 11959585
references: Antimicrob Agents Chemother. 2011 Feb;55(2):567-74
references: 21078950
references: Am J Kidney Dis. 2001 Oct;38(4):E20
references: 11576907
references: J Antimicrob Chemother. 2004 Mar;53(3):441-4
references: 14963069
references: Lancet Infect Dis. 2004 Aug;4(8):528-31
references: 15288827
references: J Antimicrob Chemother. 2003 Apr;51(4):1041-2
references: 12654741
references: J Infect Dis. 2010 Sep 1;202(5):745-51
references: 20629533
references: Eur Respir J. 2012 Dec;40(6):1430-42
references: 22496332
references: J Antimicrob Chemother. 2012 Jun;67(6):1503-7
references: 22403262
references: J Antimicrob Chemother. 2004 Feb;53(2):325-8
references: 14729733
references: Antimicrob Agents Chemother. 2006 Jun;50(6):2042-9
references: 16723564